2024
Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis
Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson C, Jenkins G, Consortium R, Cavalcanti A, Mojibian A, Bravery A, Goodwin A, Etges A, Boshoff A, Guenther A, Briggs A, Palmer A, Wilson A, Crawshaw A, Anna-MariaHoffmann-Vold A, Holland A, Gordon A, Prasse A, Tzouvelekis A, Trachalaki A, Wells A, Nair A, Wendelberger B, Hope-Gill B, Gooptu B, Baldi B, Crestani B, Polanczyk C, Vancheri C, Robalo C, Summers C, Grainge C, Ryerson C, von Garnier C, Huntley C, Ravaglia C, Valenzuela C, Hayton C, McCarthy C, Chambers D, Wang D, Bablis D, Thicket D, Turner D, Talwar D, Adegunsoye D, Anand D, Dhasmana D, Parek D, Griffiths D, Richards D, Santucci E, Bendstrup E, Balestro E, Tsitoura E, Falaschetti E, Karlsen E, Gupta E, Farrand E, Khan F, Chua F, Martinez F, Bonella F, Lombardi F, Hunninghake G, Saini G, Chalmers G, Jenkins G, Gudmundsson G, Collard H, Parfrey H, Prosch H, Fainberg H, Adamali H, Stewart I, Forrest I, Glaspole I, Bauer-Ventura I, Noth I, Cox I, Strambu I, Sellares J, Eaden J, Johnston J, Swigris J, Blaikley J, Kim J, Chung J, Lasky J, Jacob J, Lee J, Behr J, Storrer K, Negrelli K, Lewandowska K, Johnson K, Antoniou K, Hostettler K, Johannson K, Hurley K, Hett K, Schwarzkopf L, Fabbri L, Price L, Pearmain L, Kawano-Dourado L, Galvin L, Spencer L, Watson L, Crowley L, Richeldi L, Piccari L, Chambour M, Molina-Molina M, Jones M, Spears M, Toshner M, Wijsenbeek-Lourens M, Brutsche M, Vasakova M, Quintana M, Gibbons M, Henry M, Keane M, Kreuter M, Hatieganu M, Sadatsafavi M, Kaminski N, Chaudhuri N, Weatherley N, Hirani N, Babes O, Spagnolo P, Beirne P, Bryce P, George P, Molyneaux P, Ortega P, Crisan-Dabija R, Maida R, Borie R, Lewis R, Rolo R, Guler S, Paganoni S, Singh S, Freitas S, Piciucchi S, Malik S, Barratt S, Hart S, Dal Corso S, Fletcher S, Stanel S, Bianchi S, Jones S, Adams W. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis. BMJ Open Respiratory Research 2024, 11: e002163. PMID: 38413120, PMCID: PMC10973691, DOI: 10.1136/bmjresp-2023-002163.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseMycophenolate mofetilRandomised controlled trialsPrimary endpointLung diseasePulmonary functionEfficacy of mycophenolate mofetilPreservation of pulmonary functionInterstitial lung disease diagnosisMMF efficacyPrimary endpoint analysisProspective observational studySystematic reviewNo language restrictionsGrading of RecommendationsAzathioprine efficacyConcomitant steroidsAzathioprine treatmentImmunomodulatory treatmentRandomised controlled trial designSecondary endpointsPlacebo comparatorRetrospective studyAzathioprineSubgroup analysis
2022
Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis
Lannes A, Farhat L, Del Giovane C, Cipriani A, Revet A, Cortese S. Comparative cardiovascular side effects of medications for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. BMJ Open 2022, 12: e062748. PMID: 36167386, PMCID: PMC9516066, DOI: 10.1136/bmjopen-2022-062748.Peer-Reviewed Original ResearchConceptsRandomised controlled trialsSystematic reviewNetwork Meta-AnalysisAttention-deficit/hyperactivity disorderCochrane Risk of Bias tool—version 2Meta-analysisCross-over randomised controlled trialConfidence of evidenceStandardised mean differencePreferred Reporting ItemsSide effects of medicationsMeta-Analysis guidelinesRisk of biasPeer-reviewed journalsNetwork Meta-Analysis toolDiagnosis of attention-deficit/hyperactivity disorderSafety of medicationsPrimary diagnosis of attention-deficit/hyperactivity disorderNo language restrictionsPublic health standpointBlood pressureEffects of medicationCochrane riskReporting ItemsSystolic blood pressure
2012
The association between metabolic syndrome and primary liver cancer: A meta-analysis.
Jinjuvadia R, Njei B, Ditah I. The association between metabolic syndrome and primary liver cancer: A meta-analysis. Journal Of Clinical Oncology 2012, 30: 175-175. DOI: 10.1200/jco.2012.30.4_suppl.175.Peer-Reviewed Original ResearchMetabolic syndromeEgger's testPrimary liver cancerIncreased risk of PLCRisk of primary liver cancerPublication biasVisual inspection of funnel plotsRisk of liver cancerInspection of funnel plotsComprehensive Meta-Analysis version 2 softwareFunnel plot inspectionCase-control studyOverall risk ratioRandom-effects modelNo language restrictionsLiver cancerBetter-designed studiesDevelopment of cancerNCEP/ATP IIIFunnel plotIdentified articlesCochrane Library databasesRisk ratioLanguage restrictionsInsulin resistance syndrome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply